A major theory of aging is that oxidative damage and mitochondrial dysfunction may play a role and this may contribute to the age-dependent incidence of neurodegenerative diseases such as Alzheimer's disease (AD). Mitochondrial dysfunction could play either a primary role or a secondary role as a risk factor in the pathogenesis of AD. Recent studies of peripheral tissues show age-dependent impairment of mitochondrial function however little information is available concerning the effects of aging on either mitochondrial function or oxidative damage to DNA or proteins in human brain. Our fist specific aim will be to determine whether there are age-dependent changes in the activities of the 4 mitochondrial electron transport chain complexes and ATP synthase in human brain tissue of neuropathologically normal individuals aged 30 to 100. We will determine the regional distribution of any changes and whether they correlate with markers of oxidative damage to DNA and protein. Measurements of 8-hydroxy-2-deoxyguanosine will be made as a marker for oxidative damage to nuclear and mitochondrial DNA, while measurements of protein carbonyl groups will be an indicator of oxidative damage to proteins. Or second specific aim is to determine whether there is an abnormality in any of the electron transport chain complexes and ATP synthase in AD postmortem brain tissue as compared with age-matched controls. We will determine whether changes are confined to one enzyme complex, and the regional distribution of changes. We will also determine whether markers of oxidative damage to DNA and protein are increased in AD mutations in mitochondrial DNA which have been associated with AD pathology. We will be able to compare neurochemical changes in these brains with those which occur in sporadic AD brains. In order to determine whether energy deficits are localized to brain or exist systemically, we will also look for evidence of mitochondrial dysfunction and oxidative damage to DNA in lymphoblastoid cell lines from familial AD patients a compared with normal controls. Finally, we will develop experimental animal models to determine whether either local or systemic administration of mitochondrial toxins can reproduce the pattern of cellular damage, and some of the characteristic histopathologic and neurochemical features of AD. We will focus on changes in the entorhinal cortex and hippocampus. We are particularly interested in developing a model involving chronic systemic administration of a mitochondrial toxin, and to determine the effects of aging on the lesions. We will also investigate potential therapeutic strategies in these models. These studies will help to elucidate the role of mitochondrial dysfunction and oxidative damage to DNA and protein in both normal aging and in the pathogenesis of AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG011337-05
Application #
6098485
Study Section
Project Start
1998-04-01
Project End
2000-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Weissmiller, April M; Natera-Naranjo, Orlangie; Reyna, Sol M et al. (2015) A ?-secretase inhibitor, but not a ?-secretase modulator, induced defects in BDNF axonal trafficking and signaling: evidence for a role for APP. PLoS One 10:e0118379
Liu, Qing; Waltz, Shannon; Woodruff, Grace et al. (2014) Effect of potent ?-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71:1481-9
Young, Anne B (2009) Four decades of neurodegenerative disease research: how far we have come! J Neurosci 29:12722-8
Swerdlow, N R; Young, A B (2001) Neuropathology in Tourette syndrome: an update. Adv Neurol 85:151-61
Cha, J H; Farrell, L A; Ahmed, S F et al. (2001) Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol Dis 8:90-102
Montine, T J; Shinobu, L; Montine, K S et al. (2000) No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Ann Neurol 48:950
Chin, J Y; Knowles, R B; Schneider, A et al. (2000) Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J Neuropathol Exp Neurol 59:966-71
Standaert, D G; Friberg, I K; Landwehrmeyer, G B et al. (1999) Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat. Brain Res Mol Brain Res 64:11-23
Knowles, R B; Chin, J; Ruff, C T et al. (1999) Demonstration by fluorescence resonance energy transfer of a close association between activated MAP kinase and neurofibrillary tangles: implications for MAP kinase activation in Alzheimer disease. J Neuropathol Exp Neurol 58:1090-8
Montine, T J; Beal, M F; Robertson, D et al. (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology 52:1104-5

Showing the most recent 10 out of 50 publications